



EXECUTIVE OFFICE OF HEALTH AND HUMAN SERVICES  
**COMMONWEALTH OF MASSACHUSETTS**  
OFFICE OF MEDICAID  
ONE ASHBURTON PLACE, BOSTON, MA 02108



**MAURA T. HEALEY**  
GOVERNOR

**KATHLEEN E. WALSH**  
SECRETARY

**KIMBERLEY DRISCOLL**  
LIEUTENANT GOVERNOR

**MIKE LEVINE**  
ASSISTANT SECRETARY  
FOR MASSHEALTH

April 3, 2023

Chair Michael J. Rodrigues  
Senate Committee on Ways and Means  
State House, Room 212  
Boston, MA 02133

Chair Aaron Michlewitz  
House Committee on Ways and Means  
State House, Room 243  
Boston, MA 02133

Chair Cindy F. Friedman  
Joint Committee on Health Care Financing  
State House, Room 313  
Boston, MA 02133

Chair John Lawn, Jr.  
Joint Committee on Health Care Financing  
State House, Room 236  
Boston, MA 02133


Dear Chairs Rodrigues, Michlewitz, Friedman, and Lawn:

Chapter 126 of the Acts of 2022 line item 4000-0300 requires the Executive Office of Health and Human Services to submit a quarterly report including the projected total costs for the next fiscal year of pharmaceutical pipeline drugs identified by the executive office and expected to be made available for utilization within a 12-month period.

The Executive Office of Health and Human Services has identified 129 new pipeline market entries from 121 manufacturers expected to be made available for utilization between April 1, 2023 and March 31, 2024. The estimated spend on the expected utilization of these products for all MassHealth members (including members enrolled with managed care) is approximately \$17.1M for the same time-period. The prior quarterly report estimated an increased spend of \$22.1M based on the addition of 143 new pipeline market entries, from 130 manufacturers. The change from the last quarterly report was largely driven by the expected approval of two rare disease therapies and one hemophilia agent, prior to the evaluation period, which would no longer be considered pipeline products. This accounts for the approximately \$4.7M decrease from the previous report.

I am grateful for your continued support of the MassHealth program. Please feel free to contact Sarah Nordberg at [Sarah.Nordberg@mass.gov](mailto:Sarah.Nordberg@mass.gov) should you have any questions about this report.

Sincerely,

A handwritten signature in black ink that reads "Mike Levine". The signature is written in a cursive style with a large, stylized "M" and "L".

Mike Levine

cc: Kathleen E. Walsh